Search alternatives:
step decrease » sizes decrease (Expand Search), we decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a non » _ non (Expand Search)
step decrease » sizes decrease (Expand Search), we decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a non » _ non (Expand Search)
-
801
Image2_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF
Published 2022“…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
-
802
Table2_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.DOCX
Published 2022“…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
-
803
Image11_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF
Published 2022“…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
-
804
Image3_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF
Published 2022“…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
-
805
Image13_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF
Published 2022“…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
-
806
Image14_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF
Published 2022“…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
-
807
Image1_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF
Published 2022“…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
-
808
-
809
-
810
Table2_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.docx
Published 2022“…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
-
811
Table1_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.xlsx
Published 2022“…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
-
812
Table1_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.xlsx
Published 2022“…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
-
813
Table2_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.docx
Published 2022“…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
-
814
-
815
-
816
Dose response association of objective physical activity with mental health in a representative national sample of adults: A cross-sectional study
Published 2018“…For daily steps, inverted U-shaped curve suggested increasing benefits until a plateau between 5 000 and 16 000 steps. …”
-
817
-
818
Effects of ROCK inhibitors H-1152 and Y-27632 on TNF-induced MLC phosphorylation, actin and CL5 reorganization and the fall in TEER.
Published 2015“…D) Effects of H-1152 and Y-27632 on the phase 1 and phase 2 TEER decreases induced by TNF. Starting at T<sub>0</sub>, HDMEC plated on ECIS 96-well arrays received a 1 hour pre-treatment with vehicle (top panel, n = 4, 4) or with a ROCK inhibitor, either H-1152 (at 1 or 10 μM, middle panel, n = 6, 6) or Y-27632 (at 1 or 10 μM, bottom panel, n = 6, 6). …”
-
819
-
820